Is lipoprotein-associated phospholipase A₂ correlated with cardiovascular risk in European women?
Year: 2013
Type: article
Abstract: Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an enzyme expressed in atherosclerotic plaques by inflammatory cells; thus, its measurement could contribute to the identification of patients with ruptureprone plaques 1 .Lp-PLA 2 is carried in the blood stream by low density lipoprotein (LDL) particles, where it is bound to small cholesterol-deplete LDL particles rather than to large cholesterol-enriched LDL particles.As the Lp-PLA 2 -LDL complex enters the vessel wall, the reduced phospholipid content of smaller LDL particles increases the oxidative susceptibility of those particles 1 .Among the serum markers of inflammation, the Lp-PLA 2 is correlated with the progression, extension, and severity of cardiovascular disease (CVD) as well as to a greater mortality risk after coronary heart attack 2 .In fact, Lp-PLA 2 has been recommended as an inflammatory marker for CVD risk assessment in patients with moderate or high risk based on Framingham criteria 3 .However, in a large study of individuals without known CVD, the addition of Lp-PLA 2 information to the risk scores containing total cholesterol and HDL-C led to only slight improvement in CVD prediction 4 .
Source: PubMed Central
Author: V Hirschler
Institution: El Hospital General de Agudos Carlos G. Durand
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: lipoprotein-associated phospholipase A2, cardiovascular risk, women, metabolic syndrome, inflammatory markers, cardiovascular risk prediction, coronary artery disease, ischemic stroke, LDL cholesterol, sex differences, Framingham risk score, LDL particle size, atherosclerosis, European women, prospective cohort
Open Access status: green
OpenAlex ID: W2145954309
